These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 5520728

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE.
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [Abstract] [Full Text] [Related]

  • 5. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E, Mannucci PM, Gringeri A, Tagariello G, Baudo F, Bauer KA, Rosenberg RD.
    Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA, Cabrera N, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañés M, Páez AM, Lissitchkov T.
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Preparation and clinical use of a new factor IX concentrate].
    Lopaciuk S, Poszwiński P.
    Acta Haematol Pol; 1978 Nov; 9(2):107-12. PubMed ID: 665130
    [Abstract] [Full Text] [Related]

  • 9. The preparation of the factors IX, II, and X concentrate by means of DEAE cellulos and its therapeutic effectiveness.
    Uszyński L, Poszwiński P.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1975 Nov; 102(5):591-4. PubMed ID: 54310
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T, Matysiak M, Zavilska K, Laguna P, Gercheva L, Antonov A, Cabrera N, Aznar JA, Woodward MK, Páez A.
    Haemophilia; 2011 Jul; 17(4):590-6. PubMed ID: 21299747
    [Abstract] [Full Text] [Related]

  • 12. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
    Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD.
    Blood; 1990 Dec 15; 76(12):2540-5. PubMed ID: 2265248
    [Abstract] [Full Text] [Related]

  • 13. [Analysis of F.IX-inhibitor bypassing activity contained in a commercial prothrombin complex concentrate (Proplex)].
    Sugimoto M, Fujimura Y, Okubo Y, Takahashi Y, Yoshioka A, Fukui H.
    Nihon Ketsueki Gakkai Zasshi; 1984 Aug 15; 47(5):1181-9. PubMed ID: 6516702
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Therapeutic approaches to factor X deficiency with emphasis on the use of a new clotting-factor concentrate (Konyne).
    O'Leary DS, Ruymann FB, Conrad ME.
    J Lab Clin Med; 1971 Jan 15; 77(1):23-32. PubMed ID: 5540427
    [No Abstract] [Full Text] [Related]

  • 16. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J, Peynet J, Chambost H, Négrier C, Briquel ME, Claeyssens S, Derlon-Borel A, Guérois C, Caron C, Scherrmann JM, Debray M, Bridey F.
    Thromb Haemost; 1998 Dec 15; 80(6):919-24. PubMed ID: 9869161
    [Abstract] [Full Text] [Related]

  • 17. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy.
    Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF.
    Thromb Haemost; 1997 Mar 15; 77(3):477-80. PubMed ID: 9065997
    [Abstract] [Full Text] [Related]

  • 18. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B.
    Kim HC, McMillan CW, White GC, Bergman GE, Saidi P.
    Semin Hematol; 1990 Apr 15; 27(2 Suppl 2):30-5. PubMed ID: 2094957
    [Abstract] [Full Text] [Related]

  • 19. [Non-activated and activated prothrombin complex concentrates, Proplex and Feiba, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX].
    Niiya K, Hirose S, Taguchi H, Miyoshi I.
    Rinsho Ketsueki; 1985 Jun 15; 26(6):980-4. PubMed ID: 3877825
    [No Abstract] [Full Text] [Related]

  • 20. [Importance of PPSB fraction in the treatment of hemophilia A with antibodies against factor VIII].
    Hrubisková K.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980 Jun 15; 107(4):672-82. PubMed ID: 6162735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.